Company news
Canadian Goldcamps Corp (CSE:CAMP) news
Canadian Goldcamps Corp news releases on 6ix. Latest, Sep 21, 2026: Canadian GoldCamps Reports High-Grade Gold and Manganese-Enriched Iron Formation at Mercator
Press releases & updates
Canadian GoldCamps Reports High-Grade Gold and Manganese-Enriched Iron Formation at Mercator
September 20, 2026
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
September 10, 2026
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
September 8, 2026
Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Quebec
September 1, 2026
Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec
August 31, 2026
Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec
August 17, 2026
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights  
August 13, 2026
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 4, 2026
Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project
July 28, 2026
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
July 1, 2026
New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity
June 8, 2026
Canadian GoldCamps Provides Mercator Gold Exploration Priorities & Strategy
May 25, 2026
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
Canadian GoldCamps Announces Extension of Price Protection for Non-Brokered Private Placement
April 20, 2026
Canadian GoldCamps Provides Corporate & Technical Work Program Updates
April 13, 2026
Canadian GoldCamps Announces Definitive Option Agreement with Stelmine for Courcy & Mercator Projects
March 31, 2026
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
Canadian GoldCamps Announces Non-Brokered Private Placement of up to $2 Million
March 9, 2026
CAMP4 to Participate in Upcoming Investor Conferences
March 6, 2026
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 5, 2026
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
Canadian GoldCamps Closes Second Tranche of Private Placement
January 13, 2026
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Canadian GoldCamps Closes First Tranche of Private Placement and Issues LOI Consideration Shares
January 1, 2026
Canadian GoldCamps Announces Management/Board Changes, Private Placement and Letter of Intent to Acquire Two Québec Gold Projects
December 19, 2025
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
Canadian GoldCamps Provides Update on Definitive Agreement to Acquire 70% interest in Murphy Lake Property
December 4, 2025
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 6, 2025
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
October 1, 2025
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 14, 2025
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
May 16, 2025
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
May 13, 2025
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
March 27, 2025
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
March 18, 2025
Canadian GoldCamps Amends Definitive Agreement to Acquire 70% interest in Murphy Lake Property located in the Athabasca Basin, Saskatchewan
October 22, 2024
Canadian GoldCamps Announces Voting Results from Annual General and Special Meeting
July 28, 2024
Canadian GoldCamps Enters into Definitive Agreement to Acquire 70% interest in Murphy Lake Property located in the Athabasca Basin, Saskatchewan
June 2, 2024
Canadian Goldcamps Announces Board and Management Changes
April 16, 2024
Canadian GoldCamps Enters into LOI to Acquire up to 70% interest in Murphy Lake Property located in the Athabasca Basin, Saskatchewan
February 25, 2024
Canadian GoldCamps Announces Option to Acquire Valley Springs Lithium Project in Nevada
October 6, 2022
Canadian GoldCamps Closes Second Tranche of Over Subscribed Non-Brokered Private Placement
December 16, 2021
Canadian GoldCamps Announces AGSM Results and Provides Update on Asset Sale to MegumaGold
February 3, 2021
Canadian GoldCamps Issues Corporate Update
December 8, 2020